CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
On Wednesday, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine use of Respiratory Syncytial Virus (RSV) vaccines in all adults aged 75 and above.
周三，美国疾病控制与预防中心的免疫实践咨询委员会（ACIP）投票推荐所有75岁及以上的成年人定期使用呼吸道合胞病毒（RSV）疫苗。
The panel also recommended RSV immunization for adults aged 60-74 years who are at increased risk for severe RSV disease, meaning they have certain chronic medical conditions.
该小组还建议，具有某些慢性疾病的60-74岁成年人在面临严重RSV疾病的增加风险时接种RSV免疫。
The recommendation is for adults who did not get an RSV vaccine last year. The RSV vaccine is not currently an annual vaccine.
建议针对去年未接种RSV疫苗的成年人。RSV疫苗目前不是年度疫苗。
ACIP postponed a vote on a recommendation for adults aged 50-59 years at increased risk for RSV-LRTD until additional data become available.
ACIP推迟了针对50-59岁年龄段增加RSV-LRTD风险的成年人的推荐投票，直到获得更多数据。
GSK Plc (NYSE:GSK) says it continues to generate data.
GSK公司（纽交所：GSK）表示，仍在生成数据。
The updated recommendation for people 60 and older replaces last year's recommendation to simplify RSV vaccine decision-making for clinicians and the public.
针对60岁及以上的更新建议取代了去年的建议，以简化临床医生和公众的RSV疫苗决策。
Earlier this month, the FDA expanded the approval of GSK's Arexvy for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years at increased risk, becoming the first and only vaccine FDA-approved for adults aged 50-59 who are at increased risk for RSV-LRTD.
本月早些时候，FDA扩大了GSK的Arexvy的批准范围，用于预防50-59岁增加风险的RSV下呼吸道疾病（LRTD），成为首个且唯一获得FDA批准的适用于年龄在50-59岁、面临RSV-LRTD风险的成年人的疫苗。
In the U.S., the vaccine was approved for use in adults aged 60 and older.
在美国，该疫苗获得了60岁及以上成年人的批准。
In April, Pfizer Inc (NYSE:PFE) released top-line immunogenicity and safety data from Phase 3 MONeT trial, evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of age at risk of developing severe RSV-LRTD.
4月，辉瑞公司（纽交所：PFE）发布了从18至59岁处于严重RSV-LRTD风险的成人中的MONeT试验的顶线免疫原性和安全性数据。
Citing JP Morgan analyst, Reuters highlights, "We believe consensus Arexvy forecasts may now be lowered to reflect a smaller eligible U.S. patient population, confirmed Moderna Inc (NASDAQ:MRNA) competition, and more risk around GSK's two-year revaccination interval."
引用JP摩根的分析师，路透社指出：“我们认为，Arexvy预测共识现在可能降低，以反映规模较小的美国患者人口，现已确认的Moderna公司（纳斯达克：MRNA）竞争，以及GSK的两年再接种间隔存在更多风险。”
The report also added, "The decision is a negative for GSK, which makes the Arexvy RSV vaccine."
报告还补充道：“该决定对于制造Arexvy RSV疫苗的GSK来说是负面的。”
Also Read: Why Is Moderna Stock Trading Lower On Wednesday?
还阅读：为什么Moderna股票周三交易下跌？
Price Action: GSK shares are down 1.80% at $38.15 during the premarket session at the last check on Thursday.
价格行动：按照上次周四盘前会话最后一次检查，GSK股票下跌了1.80%，至38.15美元。
Photo by JHVEPhoto on Shutterstock
照片由Shutterstock的JHVEPhoto拍摄